WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2004003512) COMPOSITIONS AND METHODS FOR DETERMINING THE SUSCEPTIBILITY OF A PATHOGENIC VIRUS TO PROTEASE INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2004/003512    International Application No.:    PCT/US2003/021023
Publication Date: 08.01.2004 International Filing Date: 01.07.2003
Chapter 2 Demand Filed:    30.01.2004    
IPC:
C12Q 1/37 (2006.01), G01N 33/569 (2006.01)
Applicants: VIROLOGIC, INC. [US/US]; 345 Oyster Point Blvd., South San Francisco, CA 94080-4811 (US)
Inventors: PARKIN, Neil, T.; (US).
PAXINOS, Ellen; (US).
CHAPPEY, Colombe; (US).
WRIN, Mary, T.; (US).
GAMARNIK, Andrea, V.; (US).
PETROPOULOS, Christos, J.; (US)
Agent: GEORGE, Nikolaos, C.; Jones Day, 222 East 41st Street, New York, NY 10017-6702 (US)
Priority Data:
60/393,234 01.07.2002 US
Title (EN) COMPOSITIONS AND METHODS FOR DETERMINING THE SUSCEPTIBILITY OF A PATHOGENIC VIRUS TO PROTEASE INHIBITORS
(FR) COMPOSITIONS ET METHODES PERMETTANT DE MESURER LA SENSIBILITE D'UN VIRUS PATHOGENE A DES INHIBITEURS DE LA PROTEASE
Abstract: front page image
(EN)The present invention provides an approach for developing an algorithm for determining the effectiveness of anti-viral drugs based on a comprehensive analysis of paired phenotypic and genotypic data guided by phenotypic clinical cut-offs. In one aspect, the algorithm allows one to provide a patient with effective treatment. It helps predict whether an infected individual will respond to treatment with an anti-viral compound, thereby allowing an effective treatment regimen to be designed without subjecting the patient to unnecessary side effects. Also, by avoiding the administration of ineffective drugs, considerable time and money is saved.
(FR)La présente invention concerne une approche permettant d'élaborer un algorithme servant à mesurer l'efficacité de médicaments antiviraux sur la base d'une analyse compréhensive par paires de données phénotypiques et génotypiques fondée sur des limites cliniques phénotypiques. Dans un aspect de l'invention, l'algorithme permet de fournir un traitement efficace à un patient. L'algorithme permet de prévoir si un individu infecté va être sensible à un traitement avec un composé antiviral et, ainsi, d'élaborer un régime thérapeutique adapté, sans soumettre le patient à des effets secondaires inutiles. Par ailleurs, le fait de ne pas administrer de médicaments inefficaces permet un gain de temps et d'argent considérable.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)